Results from a Phase 1b Study of UCB0599, an Orally Available, Brain-penetrant Inhibitor of Alphasynuclein (ASYN) Misfolding in People Living with Parkinson's Disease (PD)
NEUROLOGY（2021）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined